0001645113-22-000017.txt : 20220307
0001645113-22-000017.hdr.sgml : 20220307
20220307181857
ACCESSION NUMBER: 0001645113-22-000017
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220303
FILED AS OF DATE: 20220307
DATE AS OF CHANGE: 20220307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Benaim Ely
CENTRAL INDEX KEY: 0001632237
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37565
FILM NUMBER: 22719684
MAIL ADDRESS:
STREET 1: C/O REXAHN PHARMACEUTICALS, INC.
STREET 2: 15245 SHADY GROVE ROAD, SUITE 455
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NovoCure Ltd
CENTRAL INDEX KEY: 0001645113
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
BUSINESS PHONE: 44 (0)15 3475 6700
MAIL ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
FORMER COMPANY:
FORMER CONFORMED NAME: Novocure Ltd
DATE OF NAME CHANGE: 20150615
4
1
wf-form4_164669511463233.xml
FORM 4
X0306
4
2022-03-03
0
0001645113
NovoCure Ltd
NVCR
0001632237
Benaim Ely
C/O NOVOCURE INC.,
20 VALLEY STREAM PARKWAY, SUITE 300
MALVERN
PA
19355
0
1
0
0
Chief Medical Officer
Ordinary Shares
2022-03-03
4
A
0
17371
0
A
45570
D
Ordinary Shares
2022-03-03
4
S
0
803
74.498
D
44767
D
Ordinary Shares
2022-03-04
4
S
0
1510
70.407
D
43257
D
Options to Buy Ordinary Shares
80.59
2022-03-03
4
A
0
30422
80.59
A
2023-03-01
2032-02-29
Ordinary Shares
30422.0
30422
D
Options to Buy Ordinary Shares
80.59
2022-03-03
4
A
0
5452
80.59
A
2023-03-01
2032-02-29
Ordinary Shares
5452.0
5452
D
Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
Options to buy 5,452 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.
By: /s/ Steven Robbins, Attorney in Fact for Ely Benaim
2022-03-07